DDD by stage

Phase 1-2

Inhibrx provides clinical update on ozekibart in late line colorectal cancer

Inhibrx Biosciences, a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, has released updated interim data from its phase 1/2 study evaluating...
Read more
Phase 1-2

Positive phase 1 data for RAG-17 in amyotrophic lateral sclerosis patients with mutations in the superoxide dismutase 1 gene

Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing next-generation RNA-based medicines, has announced positive preliminary data from the single ascending dose (SAD) phase...
Read more
CRO

New non-compromise early-phase progression accelerator launched

Carbogen AMCIS introduces Sprint for early-phase development, a new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour. Sprint has been designed to...
Read more
Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In...
Read more
Phase 1-2

Tenvie doses first subject in phase 1 TNV108 trial for peripheral neuropathies

Tenvie Therapeutics has dosed the first participant in its phase 1 clinical trial of TNV108 to treat peripheral neuropathies. The trial will assess the tolerability...
Read more
Phase 3

Roche reports phase 3 study results for myelin oligodendrocyte glycoprotein antibody-associated disease

Roche has reported new findings from the phase 3 meteoroid trial of Enspryng (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease...
Read more
Commercial

Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell thermal cyclers

Bio-Rad Laboratories has launched the PTC Harmony Thermal Cycler line, designed to offer broader access to optimised workflows for PCR applications such as sequencing,...
Read more
Discovery

ImmunoForge to accelerate central nervous system drug development with innovative blood-brain barrier shuttle platform

ImmunoForge, a clinical-stage biopharmaceutical company specialising in treatments for rare and muscular diseases, is poised to redefine central nervous system (CNS) drug delivery with...
Read more
- Advertisement -spot_img
- Advertisement -
EPO Summit ad
- Advertisement -
Pharmconex ad
- Advertisement -
NLS Days ad
- Advertisement -
ILMAC ad
- Advertisement -
BIO Europe

Latest posts

Load more

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.